BioInfra Co., Ltd.
Financials
Valuation Metrics
BioInfra Co., Ltd.'s Market Cap is ₩41B. At end of 2025 it was ₩230B. Ranked #2415 of 2,421 in KR market (top 100%), #1635 of 1,640 on KOSDAQ (top 100%), #231 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 100%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 4.09B KRW | KR#2,415/2,421 Sec#231/231 |
| Revenue | 25.62B KRW | KR#2,085/2,421 Sec#146/231 |
| Net Income | -8.29B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 34.19B KRW | KR#2,310/2,421 Sec#213/231 |
| Net Assets | 12.60B KRW | KR#2,358/2,421 Sec#222/231 |
| Employees | 132 | KR#1,428/2,421 Sec#114/231 |
| Value | ||
| P/B | 0.32x | KR#375/2,421 Sec#13/231 |
| P/S | 0.16x | KR#263/2,421 Sec#2/231 |
| FCF Yield | -69.02% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -65.79% | KR#2,312/2,421 Sec#207/231 |
| ROA | -24.24% | KR#2,276/2,421 Sec#186/231 |
| Op. Margin | -20.63% | KR#2,132/2,421 Sec#147/231 |
| Revenue Growth | 4.69% | KR#1,214/2,421 Sec#119/231 |
| Financial Health | ||
| Debt Ratio | 171.38% | KR#2,008/2,421 Sec#213/231 |
| Total Debt | 12.70B KRW | KR#1,548/2,421 Sec#136/231 |
| FCF | -2.82B KRW | KR#1,380/2,421 Sec#106/231 |
| Cash | 2.83B KRW | KR#2,178/2,421 Sec#206/231 |
| Current Ratio | 0.58x | KR#2,093/2,421 Sec#198/231 |
| Dividend | ||
| Div. Growth | -25.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -84.07% | KR#2,366/2,421 Sec#227/231 |
| 1M Return | -46.16% | KR#2,373/2,421 Sec#227/231 |
| From 52W High | -84.65% | KR#2,382/2,421 Sec#226/231 |
| 1Y MDD | -84.37% | KR#2,352/2,421 Sec#224/231 |
| Trading | ||
| Volume | 131,295 shares | KR#652/2,421 Sec#58/231 |
| Trading Value | 108.5M KRW | KR#1,513/2,421 Sec#152/231 |
| Foreign Own. | 2.68% | KR#1,395/2,421 Sec#128/231 |
| Per Share | ||
| EPS | -1,704 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,590 KRW | KR#1,939/2,421 Sec#152/231 |
Company Info
The company was established in 2007 as a Contract Research Organization (CRO) and listed on the KOSDAQ market in 2023 as a small and medium-sized venture company. Its main businesses include bioequivalence tests for generic medicines, Phase 1 clinical trials for incrementally modified drugs, clinical trials for regulatory approval, immunoanalysis, and pharmaceutical quality testing. The company holds six domestic and international patents in analysis technology and automation, including for tube opening/closing devices and dispensing systems in Korea, the U.S., and Japan. Bioinfra, founded in 2007, is headquartered in Gyeonggi-do, Yongin-si.